immunogen


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to immunogen: hapten, Tolerogen

immunogen

[ə′myü·nə·jən]
(immunology)
A substance which stimulates production of specific antibody or of cellular immunity, and which can react with these products.
References in periodicals archive ?
Interrupting this process by immunizing the patient with Aphton's anti-gastrin immunogen is a precisely "targeted" therapy.
immunogen. Other organisms identified in bulk samples included Bacillus, Pseudomonas, Cladosporium, Trichoderma, and nonsporulating fungi at concentrations of [is less than] 10 CFU/ml to 6,000 CFU/ml.
acted as exclusive financial advisor to ImmunoGen and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
ImmunoGen is conducting a Phase Ib/II trial evaluating mirvetuximab soravtansine for FR-alpha-positive ovarian cancer used in combination with other anticancer agents.
A drop of human blood is presumed to have 10e11 specific antibodies that recognize different immunogens (natural antigen epitopes and antigenic mimics, mimotopes).
Experimental design: Live PPRV vaccines containing immunogen levels of 105.00 104.00 103.00 and 102.00 TCID50/ml were inoculated to the group of five beetle goats.
The IAVI-THSTI collaborative program will participate in a coordinated, global effort to create replicas of bNAb targets in the laboratory for use as immunogens, which are the active ingredients of vaccines.
Another combination of Immunogen's lead experimental drug, called Herceptin-DM1, combined Herceptin with chemotherapy to treat breast cancer patients who stop responding to Herceptin.
Maxygen is using Monogram's Neutralizing Antibody Assay in its HIV vaccine program to rapidly and accurately screen candidate immunogens produced by gene shuffling for their ability to induce antibodies that protect against a broad range of HIV variants.
But later, in May 1999, when the Data Safety Monitoring Board (DSMB) secretly unblinded the data, it recommended that the trial be stopped; "the basis for the recommendation was the lack of evidence of a difference between the HIV-1 Immunogen group and the control group with respect to clinical progression and that continuation of the study was unlikely to lead to a demonstrable difference between the groups." [2] "Before the study began, the predicted clinical endpoint event rate was 6% progression per year, meaning that 6% of 2,500 patients would progress to an AIDS defining condition or death each year.